Bruker CorpBruker Corp
Bruker Corp

Bruker Corp

BRKR
Health Care·Health Care Equipment & Supplies

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI NANO, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI NANO segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

Massachusetts; U.S.A
Market cap
$9BNo data
Revenue
$3.4B+2.1% YoY
Net income
$-8.6M−107.6% YoY
Free cash flow
$43.3M−68.2% YoY

Market

Listed stock
BRKRPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$3.4B+2.1% YoY
Operating income
$68.2M−73.1% YoY
Net income
$-8.6M−107.6% YoY
Free cash flow
$43.3M−68.2% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $2.4B, 2022 $2.5B, 2023 $3B, 2024 $3.4B, 2025 $3.4B. Operating income: 2021 $413.3M, 2022 $432.7M, 2023 $436.9M, 2024 $253.1M, 2025 $68.2M. Net income: 2021 $277.1M, 2022 $296.6M, 2023 $427.2M, 2024 $113.1M, 2025 $-8.6M. Free cash flow: 2021 $190.4M, 2022 $145.2M, 2023 $243.2M, 2024 $136M, 2025 $43.3M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
2.1%−1147 bps YoY
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $413.3M, 2022-12-31 $432.7M, 2023-12-31 $436.9M, 2024-12-31 $253.1M, 2025-12-31 $68.2M. Net income: 2021-12-31 $277.1M, 2022-12-31 $296.6M, 2023-12-31 $427.2M, 2024-12-31 $113.1M, 2025-12-31 $-8.6M. Free cash flow: 2021-12-31 $190.4M, 2022-12-31 $145.2M, 2023-12-31 $243.2M, 2024-12-31 $136M, 2025-12-31 $43.3M

Growth heatmap

2022202320242025CAGR
Revenue
+4.7%
+17.1%
+13.6%
+2.1%
+9.2%
Gross profit
+7.9%
+15.9%
+9.0%
-4.4%
+6.9%
Operating income
+4.7%
+1.0%
-42.1%
-73.1%
-36.3%
Free cash flow
-23.7%
+67.5%
-44.1%
-68.2%
-30.9%

Earnings quality

Operating cash flow
$134.1M−46.6% YoY
Net income
$-8.6M−107.6% YoY
Free cash flow
$43.3M−68.2% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 -1559%, 2024-12-31 222%, 2023-12-31 82%, 2022-12-31 93%, 2021-12-31 102%. Free cash flow: 2025-12-31 -503%, 2024-12-31 120%, 2023-12-31 57%, 2022-12-31 49%, 2021-12-31 69%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data